Executives and leaders in the medical technology (MedTech) industry confirmed during the events of «The MedTech Conference», organized by «AdvaMed» in Boston, that portfolio restructuring strategies, a focus on tuck-in M&A, and asset divestiture operations will remain the primary axis for corporate growth in light of limited capital.
Ivan Tornos, CEO of «Zimmer Biomet», pointed out during a panel discussion that the policy of massive expansion is no longer a successful strategy for the sector, explaining that his company's strategy begins with identifying the problem to be solved—whether related to efficiency, infection management, or achieving exceptional outcomes in orthopedic surgery—and then evaluating its financial viability. He explained that his company's deals are usually under $2 billion, such as its acquisitions of «Pacira BioSciences», «Monogram Technologies», and «Paragon 28», noting that the mix of the company's capabilities has shifted over the years to become equally distributed between digital technologies, robotics, and biomechanical capabilities.
For her part, Rachel Ellingson, Chief Strategy and Corporate Development Officer at «Solventum», explained how divestitures helped the company financially recover after its spin-off from «3M», as it sold its purification and filtration sector to «Thermo Fisher Scientific» for about $4.1 billion to pay off debt, which gave it the flexibility to acquire the wound care company «Acera Surgical», alongside future plans to spin off the health information systems sector.
Why This News Matters
This trend highlights a strategic shift among medical technology giants away from high-risk mega-mergers and acquisitions, focusing instead on smaller, precisely targeted deals directed at precise technologies such as robotics and wound care, which reduces operational risks and enhances capital allocation efficiency.
Investment and Innovation at Boston Scientific
In a related context, Mike Mahoney, CEO of «Boston Scientific», emphasized the importance of long-term investment in research and development and venture portfolios. He explained that groundbreaking innovations can arise internally or externally, which has prompted his company to distribute its bets across internal innovation, acquisitions, and venture capital to support entrepreneurs and startups facing the risks of developing medical science.
Financial Analysts' Outlook on the Medical Technology Sector
Meanwhile, Robbie Marcus, financial analyst at «J.P. Morgan», noted that investor interest in medical technology has reached record levels, despite fierce competition for liquidity with the artificial intelligence sector, which captures a large share of market capital. Marcus projected broad-based sales growth in the sector by 2027, provided that medical technology companies continue to introduce new products and innovations that convince investors of accelerating future revenue growth.